Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.50 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | ESR1 | P03372 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15435640 | 0.81 | TBXAS1 (0.54) | TBXAS1PRKCIBRD4CREBBPNAMPT | |
| SCHEMBL24339261 | 0.77 | TBXAS1 (0.57) | TBXAS1PRKCIBRD4CREBBPNAMPT | |
| SCHEMBL23686560 | 0.77 | TBXAS1 (0.50) | TBXAS1PRKCIBRD4CREBBPNAMPT | |
| SCHEMBL20963444 | 0.75 | TBXAS1 (0.49) | TBXAS1GABRA1GABRB2NAMPTIDO1 | |
| SCHEMBL18760629 | 0.73 | HTT (0.30) | RAB9A | |
| SCHEMBL26108096 | 0.71 | TBXAS1 (0.48) | TBXAS1NAMPTKDM4EALDH1A1POLB | |
| SCHEMBL23055267 | 0.70 | PRKCI (0.39) | TBXAS1PRKCIBRD4CREBBPNAMPT | |
| SCHEMBL18711999 | 0.70 | MAPK1 (0.36) | GABRA1GABRB2MAPK1CYP2C9 | |
| SCHEMBL23665220 | 0.69 | GABRA1 (0.34) | GABRA1GABRB2KDM4EHPGDHSD17B10 | |
| SCHEMBL21517504 | 0.68 | MET (0.37) | GABRA1GABRB2NAMPTESR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11214538-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-11168079-B2 | Alkene compounds as farnesoid x receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210032195-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2021-02-04 | — | — | US | disclosed |
| US-10822326-B2 | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10806733-B2 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200283430-A1 | ALKENE COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-10 | — | — | US | disclosed |
| US-20200190058-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20190160060-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806733-B2 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | HBB, HBG2, MB | TBXAS1 112/4885PRKCI 2088/4885GABRA1 639/4885 |
| US-20210032195-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | TBXAS1 309/4885PRKCI 1161/4885GABRA1 471/4885 |
| US-11214538-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | TBXAS1 309/4885PRKCI 1161/4885GABRA1 471/4885 |
| US-20200190058-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | TBXAS1 407/4885PRKCI 1788/4885GABRA1 933/4885 |
| US-10822326-B2 | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation | HBB, HBG2, MB | TBXAS1 407/4885PRKCI 1788/4885GABRA1 933/4885 |
| US-11168079-B2 | Alkene compounds as farnesoid x receptor modulators | FXR1, NR1H2, NR1H4 | TBXAS1 647/4885PRKCI 2564/4885GABRA1 1099/4885 |
| US-20200283430-A1 | ALKENE COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H2, NR1H4 | TBXAS1 647/4885PRKCI 2564/4885GABRA1 1099/4885 |
| US-20190160060-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | TBXAS1 112/4885PRKCI 2088/4885GABRA1 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.